News
Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.
U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...
Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...
Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...
Pfizer reported a jump in second quarter profits Tuesday behind higher sales of Covid 19 products and some other ...
Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...
The drug maker reports second-quarter earnings Tuesday, and investors continue to eye a list of glaring problems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback